We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Alirocumab (Praluent)is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Alirocumab (Praluent) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2015–2025 with a typical study size of 2,341 participants.
Based on 6 studies · 1 meta-analysis · 4 RCTs · 22,206 total participants
Confidence
ModerateBy outcome
Alirocumab (Praluent) has an evidence score of 4.5/10 — strong evidence based on 6 indexed studies, including 2 meta-analyses. A fully human monoclonal-antibody PCSK9 inhibitor (Praluent), injected under the skin every 2 weeks, that lowers LDL cholesterol by ~50–60%. In the ODYSSEY OUTCOMES trial of ~18,900 post-heart-attack patients it reduced major cardiovascular events and showed a possible all-cause mortality signal. Generally well tolerated; injection-site reactions and high cost/access are the main trade-offs. Prescription drug, not a supplement. Representative study: PMID 39304616.
The commonly studied dose of Alirocumab (Praluent) is Prescription dosing is 75 mg or 150 mg subcutaneously every 2 weeks (a 300 mg every-4-weeks option exists), titrated by a clinician to the LDL-C target. A prescription drug; not a self-administered supplement regimen.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Nicotinamide Riboside
Mostly mechanism / observationalA vitamin B3 precursor that reliably raises cellular NAD+ levels and is well tolerated — but human trials have so far shown mostly null or mixed results on the functional outcomes (muscle, metabolism, blood pressure, cognition) that elevation is meant to drive.
Canagliflozin
Last reviewed June 2026 · evidence from 6 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Alirocumab (Praluent) — PCSK9-inhibitor monoclonal antibody
A fully human monoclonal-antibody PCSK9 inhibitor (Praluent), injected under the skin every 2 weeks, that lowers LDL cholesterol by ~50–60%. In the ODYSSEY OUTCOMES trial of ~18,900 post-heart-attack patients it reduced major cardiovascular events and showed a possible all-cause mortality signal. Generally well tolerated; injection-site reactions and high cost/access are the main trade-offs. Prescription drug, not a supplement.
Alirocumab has strong randomized human-outcome evidence: ODYSSEY OUTCOMES (~18,900 post-ACS patients) showed reduced major cardiovascular events and a possible all-cause mortality signal, on top of consistent ~50–60% LDL-C lowering across LONG TERM and familial-hypercholesterolemia trials and supporting meta-analyses. The score reflects genuinely strong cardiovascular evidence balanced against practical trade-offs — a subcutaneous injection with injection-site reactions, and high cost/access barriers — for a prescription drug presented as informational, not a recommendation.
Alirocumab is a fully human monoclonal antibody that inhibits PCSK9 (proprotein convertase subtilisin/kexin type 9).
PCSK9 normally binds the LDL receptor on liver cells and marks it for degradation; by blocking PCSK9, alirocumab spares LDL receptors so they keep recycling to the cell surface and clearing LDL cholesterol from the blood.
The result is a large LDL-C reduction — roughly 50–60% on top of statin therapy — that is mechanistically distinct from statins (which raise receptor expression) and additive to them. It is given as a subcutaneous injection, typically 75 mg or 150 mg every two weeks (a monthly 300 mg option also exists).
The landmark human-outcome evidence is ODYSSEY OUTCOMES (Schwartz 2018, NEJM): in ~18,900 patients with a recent acute coronary syndrome already on intensive statins, alirocumab significantly reduced major adverse cardiovascular events (death from coronary heart disease, non-fatal MI, ischemic stroke, or unstable-angina hospitalization), with a possible reduction in all-cause mortality — a signal that strengthened in higher-risk subgroups.
Supporting trials (ODYSSEY LONG TERM, ODYSSEY FH I/II) confirm the durable, large LDL-lowering across high-risk and familial-hypercholesterolemia populations, and an imaging trial (ODYSSEY J-IVUS) examined coronary atheroma.
Alirocumab is a sibling of evolocumab — the same PCSK9-inhibitor class with the same mechanism and broadly similar effects.
The honest trade-offs are practical rather than toxic: injection-site reactions are the most characteristic adverse event, the antibody must be injected (not a pill), and historically high cost plus prior-authorization hurdles have limited access.
Alirocumab is a prescription drug for lipid management — it is presented here as a gated, informational research entry, not a supplement and not a recommendation.
A fully human monoclonal antibody binds circulating PCSK9, preventing it from tagging LDL receptors for degradation.
With PCSK9 blocked, LDL receptors recycle back to the hepatocyte surface and keep clearing LDL-C from blood, lowering LDL ~50–60%.
Sustained, very low LDL-C reduces atherosclerotic plaque burden and major cardiovascular events in high-risk patients.
How Alirocumab (Praluent) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Prescription dosing is 75 mg or 150 mg subcutaneously every 2 weeks (a 300 mg every-4-weeks option exists), titrated by a clinician to the LDL-C target. A prescription drug; not a self-administered supplement regimen.
Loading: No loading dose; typically started at 75 mg every 2 weeks and up-titrated to 150 mg if further LDL-C lowering is needed.
Can be taken without food
| Form | Type |
|---|---|
| 💊Subcutaneous prefilled pen/syringe (alirocumab) | Recommended |
| 💊Evolocumab (Repatha) — sibling PCSK9 inhibitor with parallel cardiovascular evidence | Alternative |
| 💊Inclisiran — small-interfering-RNA PCSK9-lowering agent with less-frequent dosing | Alternative |
Alirocumab has the specific ODYSSEY OUTCOMES post-ACS data; evolocumab shares the class mechanism and outcome evidence.
Minimum: 12 weeks
Optimal: 52 weeks
Cycling: Not required
Note: Injected subcutaneously every 2 weeks at a consistent interval; rotate sites and let refrigerated pens warm to room temperature first.
Dose-response data unavailable. The current published research for Alirocumab (Praluent) does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Lowers LDL cholesterol by roughly 50–60% on top of statin therapy — additive and mechanistically distinct from statins.
In ODYSSEY OUTCOMES, reduced major adverse cardiovascular events in patients with recent acute coronary syndrome.
ODYSSEY OUTCOMES showed a possible reduction in all-cause mortality, strongest in higher-risk subgroups.
Local redness, itching, or swelling at the injection site is the most characteristic adverse event of the class.
A subcutaneous biologic with historically high cost and prior-authorization hurdles that limit real-world access.
Avoid — limited human data; lipid-lowering therapy is generally paused during pregnancy.
Often a candidate group, but use is clinician-directed and access-dependent.
A studied indication (ODYSSEY FH I/II); manage under a lipid specialist.
Intended additive combination — alirocumab is designed to be layered on statins for further LDL-C lowering; not an adverse interaction.
Commonly combined; additive LDL-C lowering with no major safety interaction.
Tip: Local redness/itching/swelling; rotate sites and warm the pen to room temperature to reduce reactions.
Tip: Generally self-limited; reported at low rates above placebo in trials.
Tip: Discontinue and seek care for serious allergic reactions; rare in trials.
Timing is flexible for Alirocumab (Praluent) — consistent daily use matters more than the time of day. A subcutaneous injection whose absorption is independent of meals; rotate injection sites (abdomen, thigh, upper arm) to limit local reactions.
Alirocumab (Praluent) should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are injection-site reaction, nasopharyngitis / flu-like symptoms, hypersensitivity / allergic reaction. Use caution if any of these apply to you: Known serious hypersensitivity to alirocumab or excipients; Pregnancy (limited data; lipid lowering generally deferred in pregnancy).
An SGLT2-inhibitor diabetes drug (Invokana) that lowers glucose by excreting it in urine. It extended lifespan in male mice in the NIA aging program, and the SGLT2 class has strong proven cardiovascular, kidney, and heart-failure benefits in humans. Longevity benefit itself is unproven; carries genital-infection and (rarely) ketoacidosis risks. Prescription drug, not a supplement.